Xiamen Amoytop Biotech Co Ltd
SSE:688278
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Xiamen Amoytop Biotech Co Ltd
Total Current Liabilities
Xiamen Amoytop Biotech Co Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
X
|
Xiamen Amoytop Biotech Co Ltd
SSE:688278
|
Total Current Liabilities
¥707.1m
|
CAGR 3-Years
38%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Current Liabilities
¥16B
|
CAGR 3-Years
16%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Total Current Liabilities
¥8.4B
|
CAGR 3-Years
34%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Total Current Liabilities
¥2.8B
|
CAGR 3-Years
47%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Total Current Liabilities
¥2.2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
67%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Total Current Liabilities
¥1.1B
|
CAGR 3-Years
-36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Xiamen Amoytop Biotech Co Ltd
Glance View
Xiamen Amoytop Biotech Co., Ltd., nestled in the heart of China's coastal city Xiamen, unfolds its narrative as a dynamic player in the biotechnology and healthcare industries. Born from an environment brimming with innovation, the company has diligently carved its niche by focusing on the research, development, and commercialization of diagnostic reagents and test kits. Its core competency lies in crafting solutions designed for precision and reliability, addressing the ever-evolving needs of laboratories and healthcare providers. Through a blend of cutting-edge technology and a keen understanding of biological complexities, Xiamen Amoytop has established itself as a reliable partner, providing essential tools that drive accurate diagnostics and improve patient outcomes across the globe. The company generates revenue by designing and delivering an extensive array of diagnostic products that are indispensable to modern medical practices. From infectious disease diagnostics to blood-based tests, Xiamen Amoytop leverages advancements in molecular biology to offer products that elevate the standards of health diagnostics. By supplying these critical products, the company ensures a steady flow of income sourced from healthcare facilities, research institutions, and diagnostic laboratories both domestically and internationally. Through its robust distribution network and focus on quality assurance, the company continues to expand its market presence, translating its technological prowess into financial growth and global impact.
See Also
What is Xiamen Amoytop Biotech Co Ltd's Total Current Liabilities?
Total Current Liabilities
707.1m
CNY
Based on the financial report for Dec 31, 2025, Xiamen Amoytop Biotech Co Ltd's Total Current Liabilities amounts to 707.1m CNY.
What is Xiamen Amoytop Biotech Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
44%
Over the last year, the Total Current Liabilities growth was 68%. The average annual Total Current Liabilities growth rates for Xiamen Amoytop Biotech Co Ltd have been 38% over the past three years , 44% over the past five years .